DK3580220T3 - Aminotriazolpyridiner som kinasehæmmere - Google Patents

Aminotriazolpyridiner som kinasehæmmere Download PDF

Info

Publication number
DK3580220T3
DK3580220T3 DK18707498.4T DK18707498T DK3580220T3 DK 3580220 T3 DK3580220 T3 DK 3580220T3 DK 18707498 T DK18707498 T DK 18707498T DK 3580220 T3 DK3580220 T3 DK 3580220T3
Authority
DK
Denmark
Prior art keywords
aminotriazolpyridines
inhibitors
chinese
chinese inhibitors
Prior art date
Application number
DK18707498.4T
Other languages
Danish (da)
English (en)
Inventor
Junqing Guo
Amy C Hart
John E Macor
Michael E Mertzman
William J Pitts
Steven H Spergel
Scott Hunter Watterson
Murugaiah Subbaiah Murugaiah Andappan
Jie Chen
Carolyn Diane Dzierba
Guanglin Luo
Jianliang Shi
Sing-Yuen Sit
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of DK3580220T3 publication Critical patent/DK3580220T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK18707498.4T 2017-02-13 2018-02-12 Aminotriazolpyridiner som kinasehæmmere DK3580220T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762458144P 2017-02-13 2017-02-13
PCT/US2018/017755 WO2018148626A1 (en) 2017-02-13 2018-02-12 Aminotriazolopyridines as kinase inhibitors

Publications (1)

Publication Number Publication Date
DK3580220T3 true DK3580220T3 (da) 2022-01-10

Family

ID=61283335

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18707498.4T DK3580220T3 (da) 2017-02-13 2018-02-12 Aminotriazolpyridiner som kinasehæmmere

Country Status (25)

Country Link
US (3) US10913738B2 (enExample)
EP (1) EP3580220B1 (enExample)
JP (1) JP7097373B2 (enExample)
KR (1) KR102549952B1 (enExample)
CN (1) CN110520423B (enExample)
AU (1) AU2018217488B2 (enExample)
BR (1) BR112019016635A2 (enExample)
CA (1) CA3053484A1 (enExample)
CY (1) CY1124978T1 (enExample)
DK (1) DK3580220T3 (enExample)
EA (1) EA039808B1 (enExample)
ES (1) ES2902676T3 (enExample)
HR (1) HRP20212000T1 (enExample)
HU (1) HUE057801T2 (enExample)
IL (1) IL268614B (enExample)
LT (1) LT3580220T (enExample)
MA (1) MA47460A (enExample)
MX (1) MX378515B (enExample)
PL (1) PL3580220T3 (enExample)
PT (1) PT3580220T (enExample)
RS (1) RS62801B1 (enExample)
SG (1) SG11201907335UA (enExample)
SI (1) SI3580220T1 (enExample)
SM (1) SMT202200001T1 (enExample)
WO (1) WO2018148626A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3580220T3 (da) * 2017-02-13 2022-01-10 Bristol Myers Squibb Co Aminotriazolpyridiner som kinasehæmmere
DK3704118T3 (da) 2017-10-30 2022-03-14 Bristol Myers Squibb Co Aminoimidazopyrazin som kinasehæmmere
CN112262139B (zh) 2018-01-26 2023-07-25 百时美施贵宝公司 作为激酶抑制剂的氨基吡咯并三嗪
WO2020014246A1 (en) 2018-07-09 2020-01-16 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting nav1.8
EP3820860B1 (en) * 2018-07-09 2025-10-15 Lieber Institute, Inc. Pyridazine compounds for inhibiting nav1.8
JP7599411B2 (ja) 2018-09-13 2024-12-13 ブリストル-マイヤーズ スクイブ カンパニー 受容体相互作用タンパク質キナーゼ1阻害剤(ripk1)としての1h-インダゾールカルボキサミド
EP3849969B1 (en) 2018-09-13 2023-04-19 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
US12435060B2 (en) * 2019-01-25 2025-10-07 Beijing Scitech-Mq Pharmaceuticals Limited Acylamino bridged heterocyclic compound, and composition and application thereof
US20220177462A1 (en) * 2019-03-22 2022-06-09 Genfleet Therapeutics (Shanghai) Inc. Substituted heterocyclic amide compound and preparation method therefor and pharmaceutical use thereof
US12275721B2 (en) 2019-10-03 2025-04-15 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
KR20220141321A (ko) * 2020-02-13 2022-10-19 젠플리트 테라퓨틱스 (상하이) 아이엔씨. 다이하이드로나프티리딘온 화합물, 이의 제조 방법 및 이의 의학적 용도
CN114230565B (zh) * 2020-09-09 2023-10-27 成都奥睿药业有限公司 5-取代吲哚3-酰胺衍生物及其制备方法和用途
CN114262322A (zh) * 2020-09-16 2022-04-01 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
AR123793A1 (es) 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
TWI824626B (zh) * 2021-08-02 2023-12-01 大陸商勁方醫藥科技(上海)有限公司 Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
BR112023025850A2 (pt) 2021-08-10 2024-03-05 Abbvie Inc Inibidores da nicotinamida ripk1
EP4495119A4 (en) 2022-03-16 2025-06-25 Jiangsu Hengrui Pharmaceuticals Co., Ltd. FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD AND MEDICAL USE THEREOF
CN114989079B (zh) * 2022-06-21 2023-06-23 中国药科大学 Ripk1激酶靶点抑制剂及其医药用途
AR131541A1 (es) 2023-01-07 2025-04-09 Syngenta Crop Protection Ag Compuestos de carboxamida novedosos
WO2025072395A1 (en) * 2023-09-27 2025-04-03 Bristol-Myers Squibb Company Triazolopyridinyl compounds as kinase inhibitors
WO2025109114A1 (en) 2023-11-24 2025-05-30 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149629A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds
WO2025149637A1 (en) 2024-01-12 2025-07-17 Syngenta Crop Protection Ag Novel carboxamide compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1765825A1 (en) 2004-06-25 2007-03-28 Amgen Inc. Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases
CA2644910C (en) 2006-03-31 2014-01-28 Abbott Laboratories Indazole compounds
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
US8865699B2 (en) 2007-11-27 2014-10-21 Cellzome Ltd. Amino triazoles as PI3K inhibitors
WO2010007100A1 (en) * 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
JP5589003B2 (ja) 2009-02-04 2014-09-10 ヴァイティー ファーマシューティカルズ,インコーポレイテッド 脂質障害のような代謝疾患の処置のために有用な[1,3]オキサジン−2−オンの誘導体
WO2014047024A1 (en) 2012-09-18 2014-03-27 Bristol-Myers Squibb Company Iap antagonists
JP2016521737A (ja) 2013-06-10 2016-07-25 バイエル・ファルマ・アクティエンゲゼルシャフト 癌を治療するための新規な化合物
WO2016027253A1 (en) 2014-08-21 2016-02-25 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments
US10709133B2 (en) 2015-11-05 2020-07-14 Sumitomo Chemical Company, Limited Condensed heterocyclic compound
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
WO2018139436A1 (ja) 2017-01-24 2018-08-02 住友化学株式会社 縮合複素環化合物及びそれを含有する組成物
DK3580220T3 (da) * 2017-02-13 2022-01-10 Bristol Myers Squibb Co Aminotriazolpyridiner som kinasehæmmere
DK3704118T3 (da) 2017-10-30 2022-03-14 Bristol Myers Squibb Co Aminoimidazopyrazin som kinasehæmmere
CN112262139B (zh) 2018-01-26 2023-07-25 百时美施贵宝公司 作为激酶抑制剂的氨基吡咯并三嗪
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas

Also Published As

Publication number Publication date
MA47460A (fr) 2019-12-18
CN110520423B (zh) 2022-08-23
MX2019009555A (es) 2019-10-02
KR102549952B1 (ko) 2023-06-29
EP3580220A1 (en) 2019-12-18
PT3580220T (pt) 2022-01-03
AU2018217488A1 (en) 2019-10-03
WO2018148626A1 (en) 2018-08-16
US20190389859A1 (en) 2019-12-26
HRP20212000T1 (hr) 2022-04-01
SG11201907335UA (en) 2019-09-27
JP2020507582A (ja) 2020-03-12
SI3580220T1 (sl) 2022-01-31
MX378515B (es) 2025-03-11
IL268614B (en) 2021-12-01
CY1124978T1 (el) 2023-01-05
JP7097373B2 (ja) 2022-07-07
CN110520423A (zh) 2019-11-29
ES2902676T3 (es) 2022-03-29
US20250074909A1 (en) 2025-03-06
RS62801B1 (sr) 2022-02-28
PL3580220T3 (pl) 2022-02-07
HUE057801T2 (hu) 2022-06-28
EP3580220B1 (en) 2021-11-17
IL268614A (en) 2019-10-31
CA3053484A1 (en) 2018-08-16
EA039808B1 (ru) 2022-03-16
US20220315580A1 (en) 2022-10-06
KR20190117006A (ko) 2019-10-15
BR112019016635A2 (pt) 2020-04-07
SMT202200001T1 (it) 2022-03-21
LT3580220T (lt) 2021-12-27
US10913738B2 (en) 2021-02-09
EA201991915A1 (ru) 2019-12-30
AU2018217488B2 (en) 2021-09-23
US12157733B2 (en) 2024-12-03

Similar Documents

Publication Publication Date Title
DK3580220T3 (da) Aminotriazolpyridiner som kinasehæmmere
IL269196A (en) Novel inhibitors
IL263586A (en) Inhibitors of the menin-mll interaction
DK3697785T3 (da) Imidazo-pyridine forbindelser som pad-inhibitorer
DK3105218T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3105226T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3209656T3 (da) Indolcarboxamidforbindelser, der er anvendelige som kinasehæmmere
DK3704118T3 (da) Aminoimidazopyrazin som kinasehæmmere
EP3541932A4 (en) INHIBITORS OF CRISPR-CAS9
DK3277677T3 (da) 1-cyano-pyrrolidinforbindelser som usp30-hæmmere
DK3464271T3 (da) Pyrazolderivater som plasma-kallikreininhibitorer
LT3303334T (lt) Tirozinkinazės inhibitoriai
DK3768674T3 (da) Aminopyrimidinderivater som ctps1-hæmmere
DK3371190T3 (da) Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3442972T3 (da) Bromdomænehæmmere
DK3571192T3 (da) Jak1-selektive inhibitorer
BR112016030697A2 (pt) inibidores da desmetilase-1 específica da lisina
DK2981526T3 (da) Naphthylureaderivater til anvendelse som kinaseinhibitorer
DK3313832T3 (da) 3-tetrazolyl-benzen-1,2-disulfonamidderivater som metallo-beta- lactamase-hæmmere
DK3271349T3 (da) Benzimidazolederivater som bromodomain-inhibitorer
DK3538528T3 (da) Pyrrolamider som alpha v-integrinhæmmere
DK3728207T3 (da) Quinazolinoner som parp14-inhibitorer
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
DK3341379T3 (da) EZH2-hæmmere
DK3592745T3 (da) Pyrimidopyrimidinoner anvendelige som Wee-1 kinaseinhibitorer